Publication | Closed Access

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

Metastatic Breast CancerChemotherapy Versus ChemotherapyBreast OncologyMedicineRandomised Phase 3Breast CancerPharmacotherapyCancer TreatmentOncologyRadiation Oncology